Matchroom Boxing announced in August that Dillian Whyte had returned adverse analytical findings as part of a random anti-doping protocol by the Voluntary Anti-Doping Association (VADA).
His DAZN PPV fight with Anthony Joshua at London’s O2 Arena was cancelled, as a result, just seven days out.
NoSmokeSport.com revealed a few weeks later that Whyte returned an adverse finding for an experimental drug ‘Molidustat’.
Molidustat is a drug which can increase the endogenous production of erythropoietin (EPO).
Whyte’s latest fail was the third occasion in which he had produced an adverse finding. MORE
Hearn On Dillian Whyte Phone Call
Eddie Hearn, the longtime promoter of Whyte, has not spoken to him since the revelation of the banned substance but the pair had a conversation this week, Hearn told Boxing King Media.
“I actually spoke to Dillian this week for the first time not overly deeply but I do believe there could be some news coming. I’ve no idea what that news is but I guess stand by for that.”
Dean Whyte claimed last week, as well, that a positive update could be dropping on the former Heavyweight title challenger’s doping case.
“I know nothing about it. Until I see the information/hearing, I don’t know. I’ve not been involved in the process at all so I’ve no idea how that could look, I guess we’ll find out soon.”